首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >Anti-Human CD4 Induces Peripheral Tolerance in a Human CD4(+), Murine CD4(-), HLA-DR(+) Advanced Transgenic Mouse Model.
【24h】

Anti-Human CD4 Induces Peripheral Tolerance in a Human CD4(+), Murine CD4(-), HLA-DR(+) Advanced Transgenic Mouse Model.

机译:抗人类CD4诱导人类CD4(+),鼠CD4(-),HLA-DR(+)先进转基因小鼠模型的外周耐受。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Selection in vivo of potent mAbs to human CD4 useful for immunotherapy, e.g., for the induction of immunological tolerance, is restricted for ethical reasons. We therefore used multiple transgenic mice that lack murine CD4, but express human CD4 specifically on Th cells, and HLA-DR3 as its natural counterligand (CD4/DR3 mice). The injection of CD4/DR3 mice with anti-human CD4 (mAb Max.16H5) before immunization with tetanus toxoid (TT, day 0) totally blocked the formation of specific Abs. This state of unresponsiveness persisted a subsequent boost again performed in the presence of anti-human CD4. When these mice were left untreated for at least 40 days, and were then re-exposed with TT, but in the absence of anti-human CD4, they consistently failed to induce specific Abs (long-term unresponsiveness). Exposure to second party Ags (hen egg lysozyme, human acetylcholine receptor) induced specific Abs comparable with control mice, demonstrating that the anti-CD4-induced unresponsiveness was Ag specific (immunological tolerance). Importantly, the concurrent injection of TT and anti-human CD4 at day 0, followed by another two anti-CD4 treatments, also led to tolerant animals, indicating that tolerance was inducible at the same day as the Ag exposure is provided. We finally demonstrate a limited ability of spleen cells to respond to TT in vitro, indicating that T cells are essentially involved in the maintenance of TT-specific tolerance. These data show for the first time that the human CD4 coreceptor mediates tolerance-inducing signals when triggered by an appropriate ligand in vivo.
机译:由于伦理学原因,限制了体内选择可用于免疫治疗,例如用于诱导免疫耐受的人CD4的有效mAb。因此,我们使用了多个缺少鼠CD4但在Th细胞上特异性表达人CD4的转基因小鼠,以及HLA-DR3作为其天然抗配体(CD4 / DR3小鼠)。在用破伤风类毒素免疫(TT,第0天)免疫之前,用抗人CD4(mAb Max.16H5)注射CD4 / DR3小鼠完全阻断了特异性抗体的形成。这种无反应状态持续存在随后在抗人CD4存在下再次进行的增强。当这些小鼠未经治疗至少40天,然后再次与TT接触,但是在没有抗人CD4的情况下,它们始终无法诱导特异性Abs(长期无反应)。暴露于第二方Ags(鸡蛋溶菌酶,人乙酰胆碱受体)可诱导与对照小鼠相当的特异性Abs,表明抗CD4诱导的无反应性是Ag特异性的(免疫耐受性)。重要的是,在第0天同时注射TT和抗人CD4,然后再进行另外两种抗CD4治疗,也导致了动物耐受,表明在提供Ag暴露的同一天就可以诱导耐受。我们最终证明了脾细胞在体外对TT响应的能力有限,表明T细胞基本上参与了TT特异性耐受的维持。这些数据首次表明人CD4共受体在体内被适当的配体触发时介导耐受诱导信号。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号